回到未来：基于机制、突变特异性的联合化学预防与合成致死方法。
Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.
机构信息
Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.
出版信息
Cancer Prev Res (Phila). 2011 May;4(5):628-32. doi: 10.1158/1940-6207.CAPR-11-0162.
Abstract
There is an increasing recognition that the mutations accompanying carcinogenesis may provide a window of therapeutic advantage designated synthetic lethality, an example of which is reported in this issue of the journal by Huang and colleagues (beginning on page 666). First discovered and studied in yeast, synthetic lethality has basic principles that have encouraged its development for treatment and now prevention in animal models of human cancer, especially malignancies refractory to standard approaches. The pros and cons of this approach and challenges in implementing it clinically are discussed.
摘要
人们越来越认识到，伴随致癌过程的突变可能提供了一个治疗优势窗口，被称为合成致死性，这在本期杂志 Huang 和同事的报告中有所体现（见第 666 页开始）。该概念最初在酵母中被发现和研究，具有基本原则，这鼓励了其在人类癌症动物模型中的治疗和现在的预防中的发展，特别是在对抗标准方法有抗性的恶性肿瘤中。本文讨论了这种方法的优缺点和临床实施中的挑战。
相似文献
1
Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.回到未来：基于机制、突变特异性的联合化学预防与合成致死方法。
Cancer Prev Res (Phila). 2011 May;4(5):628-32. doi: 10.1158/1940-6207.CAPR-11-0162.
2
Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.体外和体内诱导突变 KRAS 前病变细胞合成致死性预防肺癌。
Cancer Prev Res (Phila). 2011 May;4(5):666-73. doi: 10.1158/1940-6207.CAPR-10-0235.
3
An intermittent approach for cancer chemoprevention.间歇性癌症化学预防方法。
Nat Rev Cancer. 2011 Nov 10;11(12):879-85. doi: 10.1038/nrc3167.
4
Applying synthetic lethality for the selective targeting of cancer.应用合成致死性实现对癌症的选择性靶向治疗。
N Engl J Med. 2014 Oct 30;371(18):1725-35. doi: 10.1056/NEJMra1407390.
5
Novel multiple, monoallelic KRAS mutations at codon 12 and 13.密码子12和13处新型多个单等位基因KRAS突变
Int J Cancer. 2009 Dec 1;125(11):2744-5. doi: 10.1002/ijc.24635.
6
[Basic principles for the prevention, diagnosis and therapy of lung cancer].[肺癌预防、诊断与治疗的基本原则]
Magy Onkol. 2012 May;56(2):114-32.
7
Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening.通过天然化合物筛选分离一种针对K-Ras诱导的p53抑制的化学抑制剂。
Int J Oncol. 2009 Jun;34(6):1637-43. doi: 10.3892/ijo_00000294.
8
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.贝沙罗汀联合厄洛替尼在两项临床试验和转基因模型中独立于 KRAS 突变抑制肺癌发生。
Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376.
9
Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.非吸烟肺癌患者呼吸复合物 I 中线粒体 DNA 突变促进肺癌进展，并与 EGFR 基因突变相关。
J Cell Physiol. 2012 Jun;227(6):2451-60. doi: 10.1002/jcp.22980.
10
KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma.KRAS 突变分析有助于鉴别原位结肠腺癌的肺转移与原发性肺腺癌。
J Thorac Oncol. 2011 Jan;6(1):220-2. doi: 10.1097/JTO.0b013e3181f8a164.
引用本文的文献
1
The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma.FEN1和RAD54B的过表达可能作为肺腺癌的独立预后因素。
PLoS One. 2015 Oct 2;10(10):e0139435. doi: 10.1371/journal.pone.0139435. eCollection 2015.
2
Short-term Intervention to Revert Premalignant Lesions as Strategy to Prevent Gastrointestinal Cancers.逆转癌前病变的短期干预作为预防胃肠道癌症的策略
J Cancer Prev. 2013 Dec;18(4):289-97. doi: 10.15430/jcp.2013.18.4.289.
3
Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.降低辐射诱发癌症的风险：药物研发中的局限性与范例
J Radiol Prot. 2014 Jun;34(2):R25-52. doi: 10.1088/0952-4746/34/2/R25. Epub 2014 Apr 14.
4
Gut microbes, diet, and cancer.肠道微生物、饮食与癌症。
Cancer Treat Res. 2014;159:377-99. doi: 10.1007/978-3-642-38007-5_22.
5
An intermittent approach for cancer chemoprevention.间歇性癌症化学预防方法。
Nat Rev Cancer. 2011 Nov 10;11(12):879-85. doi: 10.1038/nrc3167.
本文引用的文献
1
Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.体外和体内诱导突变 KRAS 前病变细胞合成致死性预防肺癌。
Cancer Prev Res (Phila). 2011 May;4(5):666-73. doi: 10.1158/1940-6207.CAPR-10-0235.
2
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.癌症风险降低（化学预防）药物的监管批准：将我们所学到的知识应用于临床。
Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014.
3
Searching for synthetic lethality in cancer.寻找癌症中的合成致死性。
Curr Opin Genet Dev. 2011 Feb;21(1):34-41. doi: 10.1016/j.gde.2010.10.009. Epub 2011 Jan 20.
4
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?化学预防、风险降低、治疗性预防还是预防性治疗？
J Natl Cancer Inst. 2010 Dec 15;102(24):1815-7. doi: 10.1093/jnci/djq466. Epub 2010 Nov 29.
5
Synthetic lethality: general principles, utility and detection using genetic screens in human cells.合成致死性：在人类细胞中使用遗传筛选检测的一般原则、效用。
FEBS Lett. 2011 Jan 3;585(1):1-6. doi: 10.1016/j.febslet.2010.11.024. Epub 2010 Nov 19.
6
Tipping the balance for the primary prevention of breast cancer.为乳腺癌的一级预防扭转平衡。
J Natl Cancer Inst. 2010 Nov 17;102(22):1683-5. doi: 10.1093/jnci/djq435. Epub 2010 Nov 4.
7
Inhibition of mutated, activated BRAF in metastatic melanoma.转移性黑色素瘤中突变激活 BRAF 的抑制。
N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.
8
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.奥拉帕利在携带 BRCA1 或 BRCA2 突变的复发性卵巢癌患者中的疗效：一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.
9
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.国家外科辅助乳腺和肠道项目（National Surgical Adjuvant Breast and Bowel Project）他莫昔芬和雷洛昔芬（Tamoxifen and Raloxifene）试验（STAR）P-2 研究更新：预防乳腺癌。
Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.
10
Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis.通过针对 APC 缺陷细胞的凋亡来预防结直肠癌。
Nature. 2010 Apr 15;464(7291):1058-61. doi: 10.1038/nature08871. Epub 2010 Mar 28.
Zotero 插件